EU
Safety governance that stands up to questions In inspections, the most common safety-system weakness is not the lack of a procedure—it’s the inability to show who did what, when, and why, consistently across partners (Sponsor, CRO, labs, sites). A practical way to prevent this is to make governance
EU
Safety governance that stands up to questions In inspections, the most common safety-system weakness is not the lack of a procedure—it’s the inability to show who did what, when, and why, consistently across partners (Sponsor, CRO, labs, sites). A practical way to prevent this is to make governance
Global
KRI design that produces decisions (not dashboards) Risk-Based Monitoring (RBM) often fails for one of two reasons: KRIs are chosen because they are easy to measure (not because they are meaningful), or thresholds are set without a documented clinical/operational rationale. The goal is to show documented oversight that is
Global
Version control and consent package completeness (the preventable findings) Informed consent findings are often basic: wrong version used, missing required signatures, missing documentation of re-consent, or inconsistent consent dates across source and systems. The way to make consent “inspection-proof” is to treat it as a controlled process with clear document
Global
Vendor qualification: risk-tiering and evidence that your selection was controlled “Vendor oversight” is not just auditing. It’s the full lifecycle of selecting, qualifying, contracting, supervising, and correcting a partner performing delegated trial activities. Inspectors generally expect sponsors to demonstrate that oversight is proportionate to risk and that responsibilities are
Global
KRI design that produces decisions (not dashboards) Risk-Based Monitoring (RBM) often fails for one of two reasons: KRIs are chosen because they are easy to measure (not because they are meaningful), or thresholds are set without a documented clinical/operational rationale. The goal is to show documented oversight that is
Global
Vendor qualification: risk-tiering and evidence that your selection was controlled “Vendor oversight” is not just auditing. It’s the full lifecycle of selecting, qualifying, contracting, supervising, and correcting a partner performing delegated trial activities. Inspectors generally expect sponsors to demonstrate that oversight is proportionate to risk and that responsibilities are
Global
PI oversight and delegation in decentralized delivery models Decentralized and hybrid trials distribute activities across locations and organizations. Inspection risk increases when the Investigator’s oversight becomes hard to see in the records. The goal is to make oversight explicit through delegation, training, communication pathways, and documented review of critical
Global
TMF planning: define ownership, timeliness, and QC before the first document TMF/eTMF quality is usually determined early: clear filing responsibilities, naming conventions, and a realistic QC model. Without these, teams drift into “we’ll fix it at the end,” which rarely works under inspection timelines. This content is operational
US
Start with a system inventory that ties to trial risks Computerized System Validation (CSV) and Computer Software Assurance (CSA) approaches both fail when teams can’t answer a basic question: Which systems matter for this trial, and why? Build a system inventory that connects each system to critical data and
Global
PI oversight and delegation in decentralized delivery models Decentralized and hybrid trials distribute activities across locations and organizations. Inspection risk increases when the Investigator’s oversight becomes hard to see in the records. The goal is to make oversight explicit through delegation, training, communication pathways, and documented review of critical
Global
Applying ALCOA+ across real trial data sources (not just EDC) ALCOA+ is easiest to discuss in theory and hardest to implement across the many systems and data pathways in modern trials. A practical approach is to map ALCOA+ attributes to each major data source and define the controls and evidence
Safety governance that stands up to questions In inspections, the most common safety-system weakness is not the lack of a procedure—it’s the inability to show who did what, when, and why, consistently across partners (Sponsor, CRO, labs, sites). A practical way to prevent this is to make governance
KRI design that produces decisions (not dashboards) Risk-Based Monitoring (RBM) often fails for one of two reasons: KRIs are chosen because they are easy to measure (not because they are meaningful), or thresholds are set without a documented clinical/operational rationale. The goal is to show documented oversight that is
Version control and consent package completeness (the preventable findings) Informed consent findings are often basic: wrong version used, missing required signatures, missing documentation of re-consent, or inconsistent consent dates across source and systems. The way to make consent “inspection-proof” is to treat it as a controlled process with clear document
Vendor qualification: risk-tiering and evidence that your selection was controlled “Vendor oversight” is not just auditing. It’s the full lifecycle of selecting, qualifying, contracting, supervising, and correcting a partner performing delegated trial activities. Inspectors generally expect sponsors to demonstrate that oversight is proportionate to risk and that responsibilities are
Start with a system inventory that ties to trial risks Computerized System Validation (CSV) and Computer Software Assurance (CSA) approaches both fail when teams can’t answer a basic question: Which systems matter for this trial, and why? Build a system inventory that connects each system to critical data and
A unified inspection readiness program (beyond a mock inspection) Modern inspections typically test your ability to retrieve records quickly, explain decisions coherently, and demonstrate active oversight across sponsors, CROs, sites, and vendors. A “unified approach” means the sponsor has a repeatable program that works regardless of agency, and that the
PI oversight and delegation in decentralized delivery models Decentralized and hybrid trials distribute activities across locations and organizations. Inspection risk increases when the Investigator’s oversight becomes hard to see in the records. The goal is to make oversight explicit through delegation, training, communication pathways, and documented review of critical
Deviation taxonomy: classify consistently so trends are meaningful Deviation programs break down when sites and monitors label similar events differently (or when everything is called “minor”). Consistent classification supports risk-based oversight and makes your CAPA system defensible. This content is operational guidance only and not legal advice. 1) Practical classification
Why CDISC matters to Clinical Operations (even if you never build a dataset) CDISC standards (notably SDTM and ADaM) shape how regulators review your study. Clinical teams influence CDISC success more than many realize because protocol design, CRF structure, and operational decisions determine whether data can be standardized cleanly. This
TMF planning: define ownership, timeliness, and QC before the first document TMF/eTMF quality is usually determined early: clear filing responsibilities, naming conventions, and a realistic QC model. Without these, teams drift into “we’ll fix it at the end,” which rarely works under inspection timelines. This content is operational
Applying ALCOA+ across real trial data sources (not just EDC) ALCOA+ is easiest to discuss in theory and hardest to implement across the many systems and data pathways in modern trials. A practical approach is to map ALCOA+ attributes to each major data source and define the controls and evidence
Implementation roadmap: turn ICH E6(R3) concepts into operating practice ICH E6(R3) emphasizes proactive quality management, proportionate oversight, and fit-for-purpose approaches in a complex ecosystem of vendors, systems, and decentralized activities. Practical implementation requires translating principles into roles, procedures, and evidence that can be demonstrated during inspection. This section